Dana-Farber Cancer Institute authors: Giuseppe Tarantino, PhD, David Liu, MD, MPH ...

The FDA has received a biologics license application submission for RP1 plus nivolumab in patients with PD-1 ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Studying patients with PD-1 or PD-L1 deficiency may help inform new approaches to fine-tuning immunotherapies to maximise ...

Findings indicate a serine/glycine-free diet can reduce colorectal cancer growth and enhance immune response, offering ...

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...

The FDA has granted LBL-024 orphan drug designation (ODD) for the treatment of neuroendocrine cancer. The agent has already ...

"In addition to the monotherapy expansion studies we are launching in 1Q25 in HNSCC, I am thrilled to announce our new ...